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Background: Since 2006, the genetic testing company 23andMe has collected biological samples, self-reported
information, and consent documents for biobanking and research from more than 1,000,000 individuals (90 %
participating in research), through a direct-to-consumer (DTC) online genetic-testing service providing a genetic
ancestry report and a genetic health report. However, on November 22, 2013, the Food and Drug Administration
(FDA) halted the sale of genetic health testing, on the grounds that 23andMe was not acting in accordance with
federal law, by selling tests of undemonstrated reliability as predictive tests for medical risk factors. Consumers
could still obtain the genetic ancestry report, but they no longer had access to the genetic health report in the
United States (US). However, this did not prevent the company from continuing its health research, with previously
obtained and future samples, provided that consent had been obtained from the consumers concerned, or with
health reports for individuals from other countries. Furthermore, 23andMe was granted FDA authorization on
February 19, 2015, first to provide reports about Bloom syndrome carrier status, and, more recently, to provide
consumers with “carrier status” information for 35 genes known (with high levels of confidence) to cause disease.
Discussion: In this Debate, we highlight the likelihood that the primary objective of the company was probably
two-fold: promoting itself within the market for predictive testing for human genetic diseases and ancestry at a low
cost to consumers, and establishing a high-value database/biobank for research (one of the largest biobanks of
human deoxyribonucleic acid (DNA) and personal information).
Summary: By dint of this marketing approach, a two-sided market has been established between the consumer
and the research laboratories, involving the establishment of a database/DNA biobank for scientific and financial
gain. We describe here the profound ethical issues raised by this setup.
Keywords: Biobanking, Data banking, Direct-to-consumer (DTC) genetic testing, Two-sided markets, Research,
Service, Ethical issuesBackground
23andMe is a company based in Mountain View,
California. This specialist company operates in the
biotechnology sector and was founded in 2006 by Linda
Avey and Anne Wojcicki. Google has been one of the
principal investors in the four rounds of investment in
this company (Table 1) [1]. 23andMe offers a direct-to-
consumer (DTC) genetic testing service based on the* Correspondence: guillaume.vogt@inserm.fr;
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(http://creativecommons.org/publicdomain/zeuse of single-nucleotide polymorphisms (SNPs) to deter-
mine ancestry and to identify genetic markers associated
with specific diseases and conditions and a few specific
causal variants that the company claimed could provide
information about their clients’ health and how to im-
prove it [2]. The approach used can be summarized in
five steps, as follows (Fig. 1): 1) online consent and or-
dering of the kit; 2) delivery of the kit to the client's
home for the collection of a saliva sample; 3) shipping of
the saliva sample to 23andMe; 4) DNA extraction and
analysis on an Illumina Human Omni Express-24 chip
(2 million SNPs covering the whole genome); 5)
provision of the genetic results online via a personalized
23andMe web account six to eight weeks after reception
of the sample by the company. However, DTC healthis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Series dates, amounts and names of the main investors in 23andMe [1]
Series Month/year Level of investment
(millions of dollars)
Invertors
Series A May 2007 9 Google, Genentech, Mohr Davidow
Ventures, New Enterprise Associates
Series B June 2009 12.5 Google, Sergey Brin
Series C (1) November. 2010 22 Johnson & Johnson Development Corporation,
New Enterprise Associates, Google Ventures
Series C (2) January. 2011 9 Johnson & Johnson Development Corporation
Series D December. 2012 50 Google Ventures, Yuri Milner, MPM Capital,
New Enterprise Associates, Sergey Brin, Anne Wojcicki
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medical prescription or information from a whole-
genome analysis (WGA) based on genome-wide associ-
ation (GWA) studies. The use of such an approach
raised questions about the reliability of the 23andMe test
in terms of the rates of true and false negatives and posi-
tives (as this test had not been validated as a health test),
and of the information delivered to consumers.
Beyond the legal issues, we focus here on the original
nature of the service provided to consumers and its
probable consequences in the near future. Indeed, given
the exponential nature of the ‘geneticization’ of medicine
and medical research [3] in the US and Europe over the
last decade, requests for DNA and biological samples
from research laboratories have greatly increased in
number. The interface between patients and research re-
mains complex and potentially conflictual, due to ethical
issues relating to the ownership of the body and of any
data pertaining to it, which are still under debate. In this
context, a simple but innovative way of proceeding may
have emerged. Given how difficult it is to obtain bio-
logical samples from a large cohort with the consent and
full history of the patients in a short space of time by
the standard route, the idea of creating an interface be-
tween individuals and researchers has emerged. Indeed,
information about human genomes, in addition to being
a personal source of useful information for treating theFig. 1 DTC genetic testing service of 23andMe, according to its websitesick or for healthy people that might become sick, could
be exploited and used as a source of profit for compan-
ies. This vision raises profound ethical issues about the
way in which subjects are included in research and
about how information about them is gained and used.
An analysis of the 23andMe website and the scientific
literature highlights how this and other American
biotech companies have specialized in medical genetics
so as to become essential intermediaries between
researchers and their research subjects, through the
generation of DNA banks and biobanks containing
hundreds of thousands of different samples provided for
DTC genetic testing.
Discussion
23andMe: the two-sided market model
According to the 23andMe website, particularly the
“Terms of Service” section, two types of service seem to
be on offer: DTC genetic testing service and participa-
tion in “23andMe Research”. The DTC genetic testing
service is the service most highlighted and best under-
stood on the website and on social networks (mostly
Facebook and Twitter). As explained above, DTC genetic
testing is based on the use of SNPs to identify genetic
markers associated with specific diseases and conditions
and a few specific causal variants. This test is a type of
whole-genome analysis (WGA) carried out with a
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genome sequencing (WGS) or whole-exome sequencing
(WES), in which all the nucleotide sequences of the
genome (WGS) or exome (WES, the exome being the
sum of all the exons present) are determined. Interest-
ingly, 85 % of all known disease-causing mutations are
in coding regions (detectable by WES) [4]. The genetic
information obtained by testing is made available to the
consumers via their own protected personal 23andMe
web accounts. The company states that its consumers
are protected by federal law, under the Genetic Entitled
Information Non-Discrimination Act (GINA). This law,
in its current state, protects Americans against discrim-
ination on the basis of genetic information. However,
according to the “Consent and Legal Agreement” (com-
mercial contract) and the “Research Consent Document”
(informed consent), consumers can agree to their genetic
information, web behavior information and self-reported
information (Fig. 2) being used in the 23andMe Research
program, the second service on offer.
23andMe Research could be considered as a voluntary
and optional service of the DTC genetic testing service.
According to the “Terms of Service”, this service is dif-
ferent from their Research and Development activity
(R&D), and is designed to improve services and to offer
new products or services to consumers. According to
the “Full Privacy Statement” section, “23andMe Research
refers to scientific research conducted by 23andMe or
third parties in collaboration with 23andMe”. The “thirdFig. 2 Definitions according to the “Full Privacy Statement” section of the 2parties” are “public, private, and government partnerships
to develop research and advance genetic understanding”.
Consumers must sign the informed consent freely avail-
able from the company’s website if they wish to make use
of this service. This option is associated with the notion of
a “full service”, because the company announces that it in-
volves the supply of additional beneficial information not
available to consumers making use of the DTC genetic
testing service only and not providing informed consent.
The third parties are the other side to the 23andMe Re-
search offer. Indeed, in exchange for information about
their genes, the consumers supply not only money, but
also web behavior information and self-reported informa-
tion. All of this information is shared with or sold to third
parties for the purposes of scientific research and
commercial applications, patents or operating licenses.
Ethically, 23andMe seems to be at the center of a flow of
information between people and research.
Can 23andMe be considered to constitute a two-sided
market strategy? By definition, a two-sided market
model is a market in which two different user groups
interact via an intermediary economic platform, known
as a “two-sided platform” [5–7]. This set-up makes pos-
sible exchanges that would not otherwise have occurred,
creating value for both sides. Both sides (in this case, the
people seeking DNA analyses and the structures seeking
to obtain information about them) can be considered to
be consumers. Two-sided markets exist in many differ-
ent types of industry, occupying the same economic3andMe website
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as those provided by Facebook, Sony or Google (Al-
phabet), for example. Such a market may exist in the
case of 23andMe, and may, indeed, always have been
planned as a business strategy. This company may ef-
fectively constitute a two-sided platform, with two kinds
of consumers: people who want information about their
own genes (for multiple reasons), and researchers and
others who want access to genetic, web behavior and self-
reported information for a large number of people (Fig. 3).
The use of this strategy enables 23andMe to obtain bio-
logical samples, DNA samples and accurate self-reported
information for DNA and biobanking (Fig. 2), with prob-
able strong positive-feedback effects on their business
model in the long term. The term “data-banking” does not
appear in the informed consent document or in any other
document on the website, including the “Privacy High-
lights” and the “Terms of Service” (www.23andme.com,
US, UK, EU and Canada). The term “bio-banking” is
used once, but only to describe the storage of saliva
samples (Fig. 2). Three separate events have favored this
approach: growing financial investment, falling prices
of genetic testing and an exponential increase in the
number of consumers over a very short period of
time (Fig. 4) [1].Fig. 3 23andMe two-sided market model. Information flows relating to the
Biological (saliva) sample flows and to and from the biobank are shown inDNA banking issues
In the past, biological samples were stored in a single
laboratory [8], but large collections of DNA samples are
becoming increasingly common in human genetics. With
the publication of the first draft sequence of the human
genome in Nature [9] and Science [10], and its completion
by the Human Genome Project, the strategic importance
of DNA banking and data collection has increased. Over
the last 10 years or so, medicine and medical research have
become increasingly “geneticized”, with the general popu-
lation becoming increasingly interested in genetic aspects.
DNA can be obtained from a number of potential sources,
including the blood, cell and tissue banks of hospital and
academic research centers, and it has been estimated that
there are already several hundred million biological sam-
ples stored in such repositories [11]. 23andMe do not state
the exact number of samples to which they have access on
their website or in other documentation, but it can prob-
ably be safely assumed that they have a collection of hun-
dreds of thousands of biological and DNA samples.
Indeed, their collection may be one of the largest available
and it is driven not only by scientific or medical aims, but
also by business imperatives [12]. 23andMe have estab-
lished a high-value biobank and database for use by private
and public research laboratories (Fig. 3).consumer and his/her body and the database are shown in blue.
green
Fig. 4 a Increasing investment in 23andMe over time. Decrease in kit price over time. November 2010: $399 or $199 + $5 less (at least one year).
March 2011: $399 or $99 + $9 per month (one year). b The almost exponential increase in the number of users coincides with the falling price of
the kit to $99 in November 2012 [1]. c Increase in the number of users over time
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rush to acquire DNA sequencing data, which may prove
to be the organic and molecular equivalent of a gold
mine. With personalized medicine, biofuels and genetic-
ally modified organisms (GMOs), the potential gene
market in 2030 is estimated to be worth as much as
$100 billion [13]. In 2001, the technology used to
sequence the human genome was still based on capillary
electrophoresis of individual fluorescently labeled Sanger
reaction products; it produced 115 thousand base pairs
per day [14] for a total cost of almost $3 billion [15]. For
30 years, until the advent of next-generation sequencing
(NGS) methods, “Sanger sequencing” was the only
method used for DNA sequencing [16]. Devices for NGS
first appeared in 2007 and owe their success to a syn-
chronous sequence analysis, resulting in faster, more
sensitive analyses at a lower overall cost [17]. Indeed,
whereas Sanger’s direct (or first-generation) sequencing
method requires the generation of DNA strands of
different lengths labeled with a fluorophore for analysis,
NGS methods reconstruct previously prepared DNA
strands by direct determination of the nucleic acids in-
corporated [18]. These methods, based on a sequencing-
by-synthesis approach, have increased sequence output
per run and read length, and have decreased costs and
improved the accuracy of base-calling [14]. With the
release of the HiSeq X Ten, the genetic sequencing
company Illumina is currently attempting to solidify its
domination of the market, with the possibility of sequen-
cing an entire genome for $1,000 [15]. However, this
offer is not yet available to everyone, as the HiSeq X Ten
system is available only as a combination of at least 10
HiSeq X machines, with each machine costing around
$1 million (Illumina source). This system could se-
quence the genomes of 18,000 humans per year. How-
ever, even if DNA sequencing costs are declining,
questions still remain about the generation, storage, ana-
lysis and interpretation standards for genetic data. This
issue is of particular relevance for DTC genetic testing,even if WGA by genome-wide SNP chip approaches are
subsequently replaced by WGS.
For DNA sequencing, a DNA source is required, and
interpretation of the genetic data generated requires
information about the source, such as clinical data or
private data for the patient. Obtaining more information
about the source improves the quality of interpretation
for genetic data and, thus, their scientific and medical
value. However, these new approaches require even
faster technology, as previously reported. In 2012,
Oxford Nanopore Technology (ONT) introduced a new
sequencing system called Minion, based on nanopores
(pores with a diameter between 1 and 100 nm). This
technology has two advantages: sample preparation is
very simple and does not require expensive reagents and
longer reads can be obtained (>1,000 bp). However, the
error rate (4 %) is currently too high for most of the
applications envisaged, including medical diagnostics.
Nevertheless, this technology may, in the near future,
provide real new opportunities for DTC testing services.
Indeed, in medicine and industry, the key issue is the
relationship between specific genetic sequences, not
necessarily restricted to SNPs or potential causal muta-
tions, and particular diseases, with a view to guiding treat-
ment and developing new drugs. This relationship is the
key to the financial value of DNA data and may be the
premise underlying the development of two-sided plat-
forms, such as that of 23andMe, for obtaining large num-
bers of samples and considerable amounts of information
for research and industry through a DTC genetic testing
service. These approaches are based on DNA banking, but
DNA sample collections may differ considerably in several
critical ways: storage, confidentiality, requests, security and
quality [19]. These aspects and the differences in them
between collections raise ethical issues.
Ethical aspects of the model
The two-sided market model of 23andMe can be consid-
ered a case study. This model raises important ethical
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research relating to autonomy, ownership of the body,
data obtained from the body, and informed consent
(Fig. 5). The people sending samples are not considered
to be patients. They are instead considered to be
consumers, and the majority are healthy. They are given
the opportunity to give informed consent for participa-
tion in scientific research, but they primarily sign a com-
mercial contract and pay for the purchase of a service,
offering genetic testing. When obtained, consent is not
given during an individual medical consultation with a
physician or a genetic counsellor at a hospital or in a
doctor’s surgery. The clients give their consent alone, via
their computer, at home. This set-up raises a major
ethical issue: that of the autonomy of the individual, in
particular, and the right to access to his or her own gen-
etic information [20]. In France, oral information
explaining the goal of testing is considered necessary.
According to French civil law, the individual does not
own his or her body and cannot ask directly for genetic
health tests to be directly. Furthermore, it remains aFig. 5 Ethical aspects of the 23andMe model and connections with Googl
database are shown in blue. Ethical issues are shown in redmatter of debate whether individuals really have the
right to access their own genetic information, their own
DNA [21, 22]. Instead, a physician must prescribe the
test, with the approval of the “Agence de Biomédecine”
(Biomedicine Agency). Moreover, the test cannot be
performed by a private company, but only by a public
genetics laboratory also approved by the “Agence de
Biomédecine”. A medical diagnosis must be based on the
sequencing of specific genes to be considered accurate.
The need to protect privacy is illustrated by the family
imbalances, preventive and curative surgery following
diagnosis and discrimination by insurance companies
that may result from poor regulation [23].
Several studies have focused on genetic tests and
raised the issue of the apparent ethical conflict between
two concepts of autonomy: some specialists from differ-
ent countries prefer to maximize autonomy, whereas
others support the notion that autonomy is only effect-
ive if accompanied by protective measures [24, 25].
Some authors have suggested that one of the prerequi-
sites for autonomous choice is that the person is able toe. Information flows relating to the consumer and his/her body and
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rational argument for his or her choice [26–28]. The
degree of autonomy of the customers of companies such
as 23andMe is highly variable, depending on genetic
competence [29]. Indeed, we can assume that the indi-
vidual’s knowledge of genetics, family history and the
penetrance or pathogenicity of the disease will determine
his or her ability to evaluate the benefits and risks of
genetic testing and the consequences for members of his
or her own family, to compare tests prescribed by a
physician and non-prescribed tests and to compare the
different DTC testing companies in terms of the quality
of the services on offer.
Two major problems relating to autonomy are imme-
diately apparent here: the problem of scientific literacy
[30] and the lack of training of physicians in genetics
[31, 32]. Indeed, it has been shown that more than half
the individuals buying genetic tests online subsequently
consult a physician to discuss the result [33]. It might
therefore be a good idea to create a “direct-to-physician
genetic reporting service”, or at least an optional service
of this kind, effective before and after the purchase of
the kit. Such a service would ensure that physicians were
better trained in the interpretation and explanation of
genetic tests and would ensure better counseling and
follow-up for users, while providing users with greater
autonomy. It would also make it possible for the test of-
fered by 23andMe to be considered a real medical diag-
nosis test rather than as simply providing information.
This vision of autonomy differs from those prevailing in
the UK and the US, in which all individuals wishing to
have access to their genetic and medical data are free to
do so, provided an agreement has been reached with the
family in cases of clinical analysis, regardless of their
level of genetic knowledge and the conditions of the
service on offer [29, 34].
The press has reported incidents in which families
requesting genetic tests via the Internet have learned,
from the results obtained, that the presumed father was
not the real biological father or in which the biological
father has found that he has children that he didn’t
know existed [35, 36]. 23andMe warns its clients in ad-
vance of the possibility of such discoveries being made
through its tests (see the website and blog of 23andMe)
and seems to have resolved this problem. It nevertheless
remains legitimate for civil society to pose the question
as to whether private companies should be able to reveal
such information through so-called “phylogeny” or
“health report” genetic testing rather than through (offi-
cial) paternity tests, particularly if they do not ensure,
other than virtually, that this choice was consented to by
all of the people concerned by the results and not just
by the principal person concerned [34]. For preventive
surgery, the best known case is undoubtedly that of anAmerican actress who underwent a prophylactic double
mastectomy following positive results in a genetic test
for the breast cancer 1 (BRCA1) mutation [37]. In the
wake of her decision, an increase was observed in the
numbers of BRCA1 and 2 tests and of prophylactic
double mastectomies carried out [38]. Over and above
the principle of not doing harm, which is called into
question by major, potentially traumatic surgery, this
approach also raises questions about the principle of
autonomy, because there may be a risk of abuse in the
long term. Indeed, if such practices were to become
systematic, insurers might have the right to oblige their
clients to undergo testing if they have a family history of
disease, particularly for genetic predispositions to cancer,
due to the costly and debilitating nature of targeted
treatments if the disease is diagnosed late.
Ethical issues also arise within the testing company.
These issues include the dematerialization and digitization
of data, the anonymization of genetic data, the confidenti-
ality of self-reported information and the storage of data
and samples (Fig. 5) [39, 40]. Indeed, when informed
consent forms and the commercial contract are signed
digitally, the consumers provide the company with their
names, together with a set of personal information about
themselves and their families relating to health and ethni-
city. The company states on its website that names,
addresses, e-mail addresses and bank data will not be
disclosed or used. Nevertheless, such information (Fig. 2)
significantly increases the medical, scientific and financial
value of the data. It is therefore unsurprising that the
contract stipulates that data, DNA and biological samples
will be kept and may be re-used in other research if the
consumer consents. With the multiplication of this
transaction by hundreds of thousands of individuals, the
company is well aware that its consumers have not only
paid a few hundred dollars each, on average, for genetic
testing services, but have actually sold their samples and
information for inclusion in a major biobank and database
for use by scientists and doctors. But what are the conse-
quences for the consumer? Can separate pieces of infor-
mation about an individual be brought together?
Particularly as concerns the consumer’s name and import-
ant items of personal information? These issues have not
been sufficiently explored by the company, which seems
to safeguard its own interests more strongly than those of
its consumers, although 23andMe received institutional
review board approval for its research protocol and a re-
vised consent document in 2010 (23andMe blog). Indeed,
Genentech has paid $60 million (in total) for the WGS
data of 3,000 23andMe consumers with Parkinson’s dis-
ease, with the aim of generating new therapeutic target
leads [41]. However, despite large amounts of clear, illus-
trated information about the phenotypes and/or diseases
revealed by their analyses, the robustness and accuracy of
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and not all of the mutations detected have been validated
by Sanger sequencing (thereby potentially mixing false
and true positives and negatives). A client may therefore
unknowingly carry a deleterious mutation that may be
reported in the information delivered by the company or
may knowingly carry such a mutation that is not identified
in the results delivered by the company. The risk of false-
positive or false-negative results for these tests is the prin-
cipal concern of the FDA and its approval process [42].
However, in the context of a study of several thousand
people (carried out by GWA), missing a single SNP in an
individual is not a problem because there are thousands of
others. At an individual level, missing a SNP may have
much greater consequences. The previous economic
model was based on low prices to attract more
consumers, providing more data and biological samples to
be valorized and sold. The four rounds of investment in
this company (Fig. 4) may have been designed to address
the problem of the probable lack of benefit from this side
of the market until the second market had been estab-
lished (Fig. 3) [43]. This second market has now been
established through the collaboration between 23andMe
and Genentech.
According to a French Agence de Biomédecine report
on genetic tests published in 2014 [44], there is currently
no consensus definition of a genetic test and very few
countries have adopted specific legislation relating to
genetic testing, the principal countries to have done so
being Austria, Switzerland, Germany and Portugal. In
the United States, genetic tests for medical purposes are
accessible without a medical prescription and are billed
by the laboratories concerned. However, 24 American
states have prohibited divulgation of the results of gen-
etic tests in the absence of a physician. Nevertheless,
companies selling genetic tests via the Internet, such as
23andMe, at least before they were prevented from
doing so by the FDA, report the results of their tests dir-
ectly to their clients. According to an Institut National
de la Santé et de la Recherche Médicale (INSERM)
report on genetic tests dating from 2008 [45], this is per-
mitted because genetic information is not considered to
be particularly sensitive in the US. Instead, it is seen as
ordinary personal information, unless supplied by a gen-
etic test governed by the FDA. Nevertheless, increasing
numbers of “genetic privacy” laws have been passed in
the US in recent years, by contrast to Europe, which
now seems to be moving in the opposite direction [44].
Indeed, the European Union (EU) is increasingly moving
towards the broader and freer circulation of data for
research purposes [44]. According to the French Agence
de Biomédicine report published in 2014 [44], the UK
has recently gone further, because the Human Genetics
Commission responsible for providing the Britishgovernment with expert advice now considers that it
would not be desirable to ban tests bought over the
Internet, simply because it would be impossible to police
such a ban given the freedom of access to the Internet
available today. However, it did recommend the estab-
lishment of a certain number of guidelines concerning
test quality, the information transmitted and the qualifi-
cations of those carrying out the test. The proof of this
shift in position is that 23andMe entered the British
market in December 2014, about a year after it was
banned by the FDA in the US [41, 46]. Ireland,
Denmark, Finland, the Netherlands and Sweden have all
accepted the sale of the 23andMe test in their territories
(23andMe Europe). It might be possible for France to
follow the same course of action. Most countries are
currently facing a change in the definition of health data
much more complex than any previously observed, which
has been neglected for far too long. It is now possible to
generate health data with non-certified medical technolo-
gies as simple as a smartphone or any kind of connected
object [47]. Is it really the fault of 23andMe for having
understood this issue or that of the health authorities for
not having thought sufficiently deeply about it?
The data and samples that 23andMe “lend” to different
research teams also raise two other ethical problems: the
inequality of access to data and samples between
research teams due to differences in financial resources
or nationality, as the laws of some countries are not
compatible with the patentability of human genes
(Fig. 5.). One direct consequence is a significant bias in
the race for publication and international tenders [39].
The issue of the patenting of human genes is far from
resolved, particularly in the US and in European coun-
tries, such as France. In the emerging world of targeted
molecular therapies and genetic tests for diagnosis and
prognosis, these questions will need to be addressed [39,
48]. There are already inequalities between research
teams in terms of the production and use of scientific
knowledge, through access to high-quality scientific pub-
lications or various new technologies, probably due to
significant qualitative and quantitative differences in
resources between countries and between research
teams in the same country. Should access to and use of
knowledge be based on the financial clout of a team or
its scientific intuition, particularly if society hopes for
new ideas to emerge from science [49]?
Another link that would merit closer scrutiny is that
connecting 23andMe to Google. Google was one of the
principal investors in all four rounds of financial invest-
ment in this company. Google may be interested in the
web behavior information for its search engine activity,
and in the self-reported information and genetic infor-
mation, which may be of use to subsidiary companies,
(e.g., X, originally Google X lab) (Fig. 5). This idea raises
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Google, with its growing monopoly on the emergence of
new technologies, ultimately resulting in a lack of
competition and, in some instances, a possible threat to
democracy. Indeed, after five years of investigation, the
European Commission accused Google of abusing its
dominance of the market in April 2015 [50]. This
example illustrates the difficulties inherent to companies
attempting both to provide services and to relay infor-
mation. 23andMe should therefore carefully consider the
risks they face, because, in this instance, the products
are biological materials and health data.
Conclusion
23andMe had the brilliant and original idea of respond-
ing to the desires of the population at a large scale. In
accordance with legislation, they offer consumers genetic
data obtained with current technology and they aim to
create a valuable biobank with data and DNA from
1,000,000 individuals. This new two-sided data-banking
market is developing more rapidly than consumer pro-
tection laws. A profound ethical reflection on the prac-
tices of this new market model is therefore required,
taking into account the history of 23andMe and other
companies. By communicating more openly with clients
and with the press about its data-banking activities,
23andMe might help the wider community to perceive
the benefits of such a large-scale donation of data
(genetic, medical and personal) to companies through
the purchase of a kit. Greater communication would also
increase transparency concerning the second market,
which is essential for the development of a lucrative
data-selling enterprise, as it would suspend the distrust
and interrogations (some based on pure fantasy) of
consumers, the scientific community and the press. As
expected, following the provision of more information
and tests to the FDA, 23andMe was granted FDA
authorization on February 19, 2015, first to provide re-
ports about Bloom syndrome carrier status [41], and,
more recently, to provide consumers with “carrier sta-
tus” information for 35 genes known (with high levels of
confidence) to cause disease [51]. Further authorizations
are likely to follow, because ethical reflections on testing
practices are now underway.
In conclusion, full information and an open mind are
essential to prevent misunderstandings. This synergy
between 23andMe and its research and commercial
partners may extend well beyond what the consumers
initially sought, with predictions for the future in which
DNA molecules are used like crystal balls. It could result
in new class actions, like those already experienced by
the company. We may now have no choice but to deal
with a new form of two-sided market model that is likely
to inspire other companies in the near future. For thesereasons, it is essential to anticipate developments through
the ethics reflections proposed by European and Canadian
bioethicists [19, 22], to help these companies to grow and
to allow scientific research to progress, while maintaining
the best possible protection of individuals.
We think that 23andMe should provide more informa-
tion about its data banking activities to its clients and
the press so that society can be made more aware of the
benefits of such a donation of data (genetic, medical and
personal) through the sale of the kit via the Internet. We
recommend greater transparency concerning the second
market the sale of the data obtained. If such an approach
had been employed from the outset, much suspicion and
many questions (some entirely based on fantasy) from
consumers, the scientific community and the press
might have been avoided, together with the class action
against the company. However, companies such as
23andMe are raising key questions that we need to
address, concerning autonomy, ownership of the body,
data relating to the body and informed consent in the
new digital age. It has now become necessary to define
new rules validated by all for the use of different
balances between consumers and patients, the services
offered and private and public healthcare, freedom and
justice in a democratic, liberal and globalized back-
ground, if we wish to construct a new world in which
the patient is fully respected by innovative genius, enter-
prise and international law.
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